Biodexa PharmaceuticalsBDRX
About: Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Employees: 13
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
0.01% less ownership
Funds ownership: 0.01% [Q3] → 0% (-0.01%) [Q4]
43% less funds holding
Funds holding: 7 [Q3] → 4 (-3) [Q4]
66% less capital invested
Capital invested by funds: $87.3K [Q3] → $29.3K (-$58K) [Q4]
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for BDRX.
Financial journalist opinion
Based on 3 articles about BDRX published over the past 30 days









